New PET tracer may predict breast cancer drug success
NCT ID NCT03321045
First seen Jan 30, 2026 · Last updated May 02, 2026 · Updated 12 times
Summary
This early-phase study tests whether a PET scan using a radioactive tracer (89Zr-trastuzumab) can show which HER2-positive breast cancer patients are likely to benefit from targeted therapy. Ten newly diagnosed adults will receive the tracer and undergo PET/MRI imaging. The goal is to see if the scan's results match standard HER2 tests and predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Kirklin Clinic
RECRUITINGBirmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.